[Home](https://github.com/mm80843/T3.5/blob/main/docs/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/main/docs/Risk/index.md) >> Individual ID:PBN__Risk_1868 

# __Lack of Effective Treatment__

## Category to which it belongs

* [The challenges include reduced surgical education, loss of control, limited diagnostics, slow drug development, inadequate patient monitoring, and lack of drug therapy options.](https://github.com/mm80843/T3.5/blob/main/docs/PBNCategory/PBN__PBNCategory_100.md)

## Closest similar item

* [Lack of treatment and resources](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2070.md)
* [Lack of novel treatment options](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2189.md)
* [Lack of effective drugs](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_2724.md)
* [Lack of drug therapy options](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1146.md)
* [Lack of effective pharmaceutical response](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1602.md)
* [Ineffective non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1490.md)
* [Insufficient non-pharmaceutical interventions](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1603.md)
* [Inadequate healthcare response](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_515.md)
* [Lack of vaccine or cure](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_1748.md)
* [Ineffective treatments based on flawed preprints](https://github.com/mm80843/T3.5/blob/main/docs/Risk/PBN__Risk_617.md)

## Description of the risk

There are no specific medicines or vaccines available to control or treat COVID-19.

## Is the risk affecting GBN scales

* [No](https://github.com/mm80843/T3.5/blob/main/docs/RiskGBN/PBN__RiskGBN_0.md)

## Type of the risk

* [physical](https://github.com/mm80843/T3.5/blob/main/docs/RiskHealth/PBN__RiskHealth_0.md)

## Type of impact of the risk (according to ISO37100)

* [Health and care](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Purpose_0.md)

## Type of purpose of the risk (according to ISO37100)

* [Resilience](https://github.com/mm80843/T3.5/blob/main/docs/RiskISO/PBN__RiskISO_Impact_2.md)

## Mitigations of this risk

* [Support ongoing research for vaccine development and antiviral medications, repurpose existing drugs for treatment](https://github.com/mm80843/T3.5/blob/main/docs/RiskMitigation/PBN__RiskMitigation_2457.md)

## Name of the risk

Increased severity and mortality rates

## Stakeholders who can mitigate this risk

* [pharmaceutical companies](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_124.md)
* [research institutions](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_413.md)

## Articles mentionning the risk

* [Nurture to nature via COVID-19, a self-regenerating environmental strategy of environment in global context](https://github.com/mm80843/T3.5/blob/main/docs/Article/PBN__Article_44.md)

## People affected by this risk

* [general population](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_9.md)
* [individuals infected with covid-19](https://github.com/mm80843/T3.5/blob/main/docs/Stakeholder/PBN__Stakeholder_686.md)

## Technologies linked to the risk

* [research and development of vaccines](https://github.com/mm80843/T3.5/blob/main/docs/Technology/PBN__Technology_1237.md)

## Property: has_RiskType

* [health](https://github.com/mm80843/T3.5/blob/main/docs/RiskType/PBN__RiskType_4.md)
* [technological](https://github.com/mm80843/T3.5/blob/main/docs/RiskType/PBN__RiskType_5.md)

